Your browser doesn't support javascript.
loading
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
Rovin, Brad H; Ayoub, Isabelle M; Chan, Tak Mao; Liu, Zhi-Hong; Mejía-Vilet, Juan M; Balk, Ethan M; Gordon, Craig E; Adam, Gaelen; Tonelli, Marcello A; Cheung, Michael; Earley, Amy; Floege, Jürgen.
  • Rovin BH; Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.
  • Ayoub IM; Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Chan TM; Division of Nephrology, Department of Medicine, University of Hong Kong, Hong Kong, China.
  • Liu ZH; National Clinical Research Center of Kidney Diseases, Nanjing University School of Medicine, Nanjing, China.
  • Mejía-Vilet JM; Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico.
  • Balk EM; Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA.
  • Gordon CE; Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
  • Adam G; Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA.
  • Tonelli MA; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Cheung M; KDIGO, Brussels, Belgium.
  • Earley A; KDIGO, Brussels, Belgium.
  • Floege J; Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany.
Kidney Int ; 105(1): 31-34, 2024 01.
Article en En | MEDLINE | ID: mdl-38182299
ABSTRACT
The Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was published in 2021. Since then, the pace of drug development for glomerular diseases has accelerated, due in large part to rapidly accumulating insights into disease pathogenesis from genetic and molecular studies of afflicted patients. To keep the Glomerular Diseases Guideline as current as possible, KDIGO made a commitment to the nephrology community to provide periodic updates, based on new developments for each disease. After the 2021 guideline was published, two novel drugs received regulatory approval for the management of lupus nephritis, leading to the first KDIGO guideline update. Herein, an executive summary of the most important guideline changes from the Lupus Nephritis chapter is provided as a quick reference.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Nefritis Lúpica / Nefrología Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Nefritis Lúpica / Nefrología Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article